Any news on advancements in Parkinson's disease treatments or medication

Between 29 and 30 October 2026, significant advancements in Parkinson's disease treatment were reported, led by the world's first post-approval stem-cell transplant in Japan using iPS cells. Additionally, a new wearable device for hand tremors received clearance, and a major cell therapy developer successfully launched an IPO to fund further clinical testing of its personalized neuron-replacement treatment.

• World's first post-approval stem-cell transplant: On 30 October 2026, Sumitomo Pharma announced that the first patient had undergone a pioneering stem-cell transplant using Amchepry (raguneprocel) at Kyoto University Hospital, following the therapy's conditional approval in Japan. 📅 Calendar file (.ics) First post-approval stem-cell transplant for Parkinson's October 30, 2026
• Aspen Neuroscience IPO for cell therapy: On 29 October 2026, Aspen Neuroscience raised $141 million in its initial public offering to advance 'sasineprocel,' a personalized cell therapy designed to replace lost dopamine-producing neurons, into deeper clinical testing. (October 30, 2026) 📅 Calendar file (.ics) Aspen Neuroscience Wall Street Debut October 30, 2026
• Wearable device cleared for hand tremors: On 30 October 2026, a new wearable device from Cala Health was cleared for treating hand tremors in Parkinson's patients, featuring adaptive calibration to adjust to changes in tremor characteristics throughout the day. 📅 Calendar file (.ics) Clearance of wearable device for Parkinson's tremors October 30, 2026
• AviadoBio gene therapy preclinical data: On 29 October 2026, AviadoBio presented data showing that its investigational gene therapy, AVB-SNCA, achieved up to 80% knockdown of the alpha-synuclein gene in human neurons, supporting its development as a one-time treatment.
• New MRI method for HIFU treatment control: Researchers reported on 29 October 2026 that a new MRI processing method improves the visualization of brain lesions during High-Intensity Focused Ultrasound (HIFU) procedures, optimizing follow-up for Parkinson's patients.

Between 27 and 28 October 2026, significant updates in Parkinson's disease research included the successful application of noninvasive focused ultrasound to ease motor symptoms and the completion of patient enrollment for a novel gut-selective therapy (VT-5006). Additionally, new clinical data for the experimental pill bezisterim showed promise in reducing brain inflammation, and a major study highlighted the effectiveness of specialized inpatient programs in preventing hospital medication errors.

• Noninvasive Focused Ultrasound for motor symptoms: On 27 October 2026, researchers reported that noninvasive focused ultrasound treatment provided immediate relief from tremors and stiffness for Parkinson's patients, offering a non-surgical alternative to deep-brain stimulation.
• Vertero Therapeutics Phase 1b enrollment completion: On 27 October 2026, Vertero Therapeutics announced the completion of patient enrollment for its Phase 1b study of VT-5006, a first-in-class gut-selective molecule designed to slow disease progression, with topline data expected by the end of 2026.
• BioVie Bezisterim Phase 2 trial results: On 28 October 2026, results from the Phase 2 SUNRISE-PD trial indicated that the oral drug bezisterim significantly improved motor and non-motor symptoms in a subgroup of patients with high inflammation markers. 📅 Calendar file (.ics) BioVie Bezisterim Phase 2 Results Presentation October 28, 2026
• Inpatient program reduces medication errors: A study published on 27 October 2026 in Annals of Neurology demonstrated that a dedicated Parkinson’s inpatient program using electronic alerts and expert support significantly reduced hospital medication errors and improved discharge outcomes.

Between 24 and 26 October 2026, significant updates in the Parkinson's treatment landscape included the announcement of a $150 million IPO by Aspen Neuroscience to fund its patient-derived cell therapy and new research into a CD38 enzyme inhibitor (CVN14) that protects neurons. Additionally, the advanced continuous infusion therapy VYALEV was introduced in the Middle East to improve symptom management for advanced cases, while the Michael J. Fox Foundation hosted a major research symposium in Washington, D.C.

• Aspen Neuroscience IPO for cell therapy: On 26 October 2026, Aspen Neuroscience set a price range for a $150 million IPO to fund the development of its patient-derived induced pluripotent stem cell (iPSC) therapy for Parkinson's disease. 📅 Calendar file (.ics) Aspen Neuroscience IPO Pricing Window October 26, 2026
• CD38 inhibitor (CVN14) research: A study reported on 26 October 2026 in Frontiers in Pharmacology identified CVN14, a small-molecule inhibitor of the CD38 enzyme, which successfully raised NAD+ levels and protected dopaminergic neurons in preclinical models. 📅 Calendar file (.ics) CD38 Inhibitor Research Publication October 26, 2026
• VYALEV introduction in Sharjah: On 26 October 2026, NMC Royal Hospital Sharjah announced the introduction of VYALEV (foscarbidopa/foslevodopa), a continuous subcutaneous infusion therapy, to provide consistent symptom control for advanced Parkinson's patients. 📅 Calendar file (.ics) VYALEV Introduction at NMC Royal Hospital October 26, 2026
• Michael J. Fox Foundation Research Symposium: The Michael J. Fox Foundation held its 'Parkinson's IQ + You' educational event in Washington, D.C., on 24 October 2026, featuring sessions on the latest clinical research and treatment options.

On 23 October 2026, researchers at the Mayo Clinic announced a first-of-its-kind clinical trial investigating low-dose radiation as an anti-inflammatory treatment to slow the progression of early-stage Parkinson's disease. Additionally, new Phase 1 data for the experimental stem cell therapy XS411 showed significant improvements in motor function and quality of life, with the Phase 2 trial now fully enrolled. These developments coincide with the commercial launch of JUVMO (tavapadon) in the United States this month.

• Mayo Clinic low-dose radiation trial: On 23 October 2026, it was reported that the Mayo Clinic is conducting the first clinical trial to test low-dose radiation as an anti-inflammatory approach to slow symptom progression in early-stage Parkinson's patients.
• XS411 stem cell therapy Phase 1 results: New Phase 1 clinical trial data for Xellsmart's XS411, reported on 23 October 2026, showed the therapy was well tolerated and improved motor function; the company also confirmed the completion of patient enrollment for its Phase 2 trial.
• Long-term exercise study results: A study published in Neurology and highlighted on 23 October 2026 found that Parkinson's patients who exercised more than eight hours per week experienced significantly slower declines in memory and movement over a seven-year period.